News

The Globe and Mail1y
ASCO SourcePacT™ Source Isolation Switch Nominated for 2024 Product of the Year - The Globe and Mail
ASCO Power Technologies' SourcePacT Source Isolation Switch, a novel solution for isolating and supplying backup power from a Battery Energy Storage System, has been nominated for the 2024 Product ...
Morningstar1mon
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination - Morningstar
TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at ...
Morningstar1mon
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis - Morningstar
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis Provided by GlobeNewswire May 21, 2025, 8:03:00 PM – Virtual KOL ...
WAVY-TV1mon
Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting - WAVY.com
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics Inc., a clinical-stage immunotherapy company specializing in the development of innovative therapies for hard-to-treat ...
Yahoo Finance4y
Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/Emphysema - Yahoo Finance
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced that ...
KXAN1mon
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic ... - KXAN Austin
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline ... Texas, May 22, 2025 (GLOBE NEWSWIRE ... multiple immune checkpoints and immune cell function.
The Globe and Mail4y
Aspira Women’s Health Releases Analytical and Initial Clinical Validation Performance for OVASight at ASCO 2021 - The Globe and Mail
AUSTIN, Texas, June 03, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on gynecologic disease, released the analytical ...
FOX31 Denver1mon
Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting - FOX31 Denver
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics Inc., a clinical-stage immunotherapy company specializing in the development of innovative therapies for hard-to-treat ...
Oklahoma's News1mon
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline ... Texas, May 22, 2025 (GLOBE NEWSWIRE ... multiple immune checkpoints and immune cell function.